| Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet |
The consensus price target hints at an 83.9% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-14 15:01:01 |
Czytaj oryginał (ang.) |
| Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript |
Zymeworks Inc. (NASDAQ:ZYME ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Senior Director, Investor Relations Ken Galbraith - Chair & CEO Paul Moore - Chief Scientific Officer Leone Patterson - Executive Vice President, Chief Business and Financial Officer Conference Call Participants Charles Zhu - LifeSci Capital Brian Cheng - JPM Stephen Willey - Stifel Jonathan Miller - Evercore ISI Amanda Acosta-Ruiz - Leerink Partners Yigal Nochomovitz - Citigroup Eva Fortea-Verdejo - Wells Fargo Robert Burns - H.C. Wainwright Operator Thank you for standing by. |
seekingalpha.com |
2025-05-09 03:00:25 |
Czytaj oryginał (ang.) |
| Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates |
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.42 per share a year ago. |
zacks.com |
2025-05-08 22:56:05 |
Czytaj oryginał (ang.) |
| Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results |
VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financial results for the three months ended March 31, 2025 and provided a summary of recent business highlights. |
globenewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline |
Zymeworks is rated Strong Buy due to its improved outlook, FDA approval of Ziihera, advancing pipeline, and strong cash position. Zanidatamab (Ziihera) is a key asset with accelerated approval for HER2+ BTC and multiple ongoing trials in high-value indications. Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside potential for investors. |
seekingalpha.com |
2025-04-28 21:33:03 |
Czytaj oryginał (ang.) |
| Zymeworks: Poised For Growth With Platform Validation |
Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3 million revenue in 2024 and a cash runway extending through late 2027. The robust pipeline includes zanidatamab for additional indications and promising early-stage candidates like ZW171 and ZW209 targeting high-unmet need cancers. |
seekingalpha.com |
2025-04-28 14:48:32 |
Czytaj oryginał (ang.) |
| Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting |
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of six posters with new preclinical data from its preclinical, development-stage, and clinical programs at the American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, IL. “The breadth of data shared at AACR highlights the strength of our oncology portfolio across antibody-drug conjugates and T cell engagers, and demonstrates the novel approaches we employ using each modality,” said Paul Moore, Ph.D. |
globenewswire.com |
2025-04-25 17:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development |
VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023, will continue as Executive Vice President & Chief Medical Officer, with primary responsibility for Zymeworks' emerging R&D portfolio in autoimmune and inflammatory disease and Global Clincal Development Operations. Ms. Barbara Schaeffler, who joined Zymeworks in 2024, has been promoted to Senior Vice President, Clinical Development Operations, reporting to Dr. Smith. |
globenewswire.com |
2025-04-21 10:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 |
VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time. |
globenewswire.com |
2025-04-17 10:00:00 |
Czytaj oryginał (ang.) |
| Insiders Make Huge Purchases of These 4 Biotech Stocks |
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations. |
247wallst.com |
2025-03-26 10:40:53 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Participation in Upcoming Investor Conferences |
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: |
globenewswire.com |
2025-03-26 08:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting |
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile |
globenewswire.com |
2025-03-25 18:30:00 |
Czytaj oryginał (ang.) |
| Huge Insider Buying: Victoria's Secret, Carl Icahn, and More |
Despite (or perhaps because of) the volatility in the stock market and uncertainty about the economy, insiders are still scooping up shares of certain stocks. |
247wallst.com |
2025-03-15 10:45:47 |
Czytaj oryginał (ang.) |
| Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 |
On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents. |
benzinga.com |
2025-03-06 15:18:27 |
Czytaj oryginał (ang.) |
| Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript |
Zymeworks Inc. (NASDAQ:ZYME ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Yigal Nochomovitz - Citi Brian Cheng - JPMorgan Jonathan Miller - Evercore ISI Jay Olson - Oppenheimer & Co. Justin Zelin - BTIG Operator Thank you for standing by. This is the conference operator. |
seekingalpha.com |
2025-03-05 22:43:19 |
Czytaj oryginał (ang.) |
| Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates |
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.20 per share a year ago. |
zacks.com |
2025-03-05 20:16:10 |
Czytaj oryginał (ang.) |
| Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financial results for the fourth quarter and year ended December 31, 2024 and provided a summary of recent business highlights. |
globenewswire.com |
2025-03-05 18:05:00 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration |
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced achievement of a $14 million cash research milestone from GSK associated with a clinical milestone. |
globenewswire.com |
2025-02-26 08:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Participation in Upcoming Investor Conferences |
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: |
globenewswire.com |
2025-02-25 08:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors |
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. |
globenewswire.com |
2025-02-18 08:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 |
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its fourth quarter and full year 2024 financial results after market close on March 5, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 5, 2025 at 4:30 pm Eastern Time (ET). |
globenewswire.com |
2025-02-13 08:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Participation in Upcoming Investor Conferences |
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: |
globenewswire.com |
2025-01-30 08:00:00 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks With Notable Insider Buying |
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners. |
seekingalpha.com |
2025-01-22 14:29:06 |
Czytaj oryginał (ang.) |
| Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 |
VANCOUVER, British Columbia, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today provided an update on key strategic priorities for 2025 and 2026. |
globenewswire.com |
2025-01-08 18:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade |
The mean of analysts' price targets for Zymeworks (ZYME) points to a 41.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-01-07 13:06:10 |
Czytaj oryginał (ang.) |
| Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule |
The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks should start generating royalties on net sales this quarter. The phase 3 results for Ziihera in first-line GEA patients are now expected in Q2 2025, and represent the next critical step for Zymeworks and its partner Jazz. |
seekingalpha.com |
2024-12-19 11:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks upgraded to Overweight from Neutral at JPMorgan |
JPMorgan upgraded Zymeworks to Overweight from Neutral with an $18 price target. |
https://thefly.com |
2024-12-16 07:22:13 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Participation in Upcoming Investor Conferences |
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-11-21 08:05:00 |
Czytaj oryginał (ang.) |
| FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) |
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced, with Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months as determined by independent central review (ICR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 The approval of Ziihera, which previously received Breakthrough Therapy Designation from the FDA for this indication, is an important advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC. |
globenewswire.com |
2024-11-21 08:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors |
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers |
globenewswire.com |
2024-11-05 08:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab |
The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HERIZON-GEA-01 study using Zanidatamab + chemotherapy plus or minus tislelizumab for treatment of patients with 1st-line GEA is expected in Q2 of 2025. Zanidatamab is being developed in collaboration with two big pharmaceutical companies, which are Jazz Pharmaceuticals and BeiGene. |
seekingalpha.com |
2024-11-04 06:28:41 |
Czytaj oryginał (ang.) |
| Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript |
Zymeworks Inc. (NASDAQ:ZYME ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief executive Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubarack - Citi Brian Cheng - JPMorgan Jon Miller - Evercore ISI Derek Achila - Wells Fargo Operator Hello. Thank you for standing by. |
seekingalpha.com |
2024-11-01 00:05:09 |
Czytaj oryginał (ang.) |
| Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates |
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.41 per share a year ago. |
zacks.com |
2024-10-31 20:20:26 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Participation in Upcoming Investor Conferences |
VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-10-29 08:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference |
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks' antibody-drug conjugate (ADC) candidates ZW220 and ZW251 in presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024. |
globenewswire.com |
2024-10-25 10:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers |
VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed in the first-in-human Phase 1 trial (NCT06523803) to evaluate the safety and tolerability of the investigational therapy ZW171 in the treatment of advanced or metastatic ovarian cancer, NSCLC, and other MSLN-expressing cancers. |
globenewswire.com |
2024-10-21 10:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024 |
VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET). |
globenewswire.com |
2024-10-10 10:30:00 |
Czytaj oryginał (ang.) |
| Zymeworks Approaching A Moment Of Truth With Zanidatamab |
ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US approval in November 2024. Subsequent approval in the same indication could follow in the EU as early as Q2 '25, and in China in H2 '25. A readout from the HERIZON-GEA-01 study of zanidatamab in gastroesophageal adenocarcinoma in Q2 '25 represents a major clinical catalyst for ZYME. |
seekingalpha.com |
2024-09-27 18:47:00 |
Czytaj oryginał (ang.) |
| Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference |
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms |
globenewswire.com |
2024-09-18 10:00:00 |
Czytaj oryginał (ang.) |
| Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c) |
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the “Nasdaq Rule”), an equity inducement award to Ms. Leone Patterson, Zymeworks' Executive Vice President and Chief Business and Financial Officer. |
globenewswire.com |
2024-09-03 20:30:00 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Participation in Upcoming Investor Conferences |
VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-08-22 10:30:00 |
Czytaj oryginał (ang.) |
| Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript |
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Bijal Desai - Vice President-Finance & Strategy Paul Moore - Chief Scientific Officer Ken Galbraith - Chair & Chief Executive Officer Pranshul Chauhan - Associate Medical Director Conference Call Participants Stephen Willey - Stifel Jon Miller - Evercore Robert Burns - H.C. Wainwright Operator Thank you for standing by. |
seekingalpha.com |
2024-08-02 02:58:09 |
Czytaj oryginał (ang.) |
| Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates |
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.76 per share a year ago. |
zacks.com |
2024-08-01 23:11:14 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock |
Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 |
globenewswire.com |
2024-08-01 20:10:00 |
Czytaj oryginał (ang.) |
| Zymeworks Announces Participation in Upcoming Investor Conferences |
VANCOUVER, British Columbia, July 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-07-30 10:30:00 |
Czytaj oryginał (ang.) |